Revenue and taxation; tax credits; biomedical and cancer research; effective date.
Summary
HB2755 amends Oklahoma’s existing income tax credit for donations to biomedical research institutes and cancer research institutes. The bill keeps the current credit structure in place through tax year 2025, then creates a new set of rules beginning in tax year 2026 that changes the annual statewide credit caps, the way the credit percentage is adjusted, and the per-taxpayer limits. It also updates the definition of an “independent biomedical research institute” by increasing the minimum annual NIH funding threshold from $15 million to $20 million.
Under the bill, donations to qualifying independent biomedical research institutes would be subject to a $1.5 million annual statewide credit cap starting in 2026, while donations to cancer research institutes would be capped at $500,000 annually. The bill also distinguishes between individual filers and business entities for the biomedical research credit, allowing larger maximum credits for business taxpayers. Existing carryforward rules remain, and the Oklahoma Tax Commission would continue to administer the credit and prescribe forms. The act would take effect November 1, 2025.
Impact
HB2755 would amend 68 O.S. 2021, Section 2357.45, which governs Oklahoma income tax credits for charitable donations to biomedical and cancer research organizations. Its practical effect is to extend and restructure the credit program for future tax years, reduce the overall annual credit availability compared with the current combined cap, and tighten eligibility for biomedical research institutes by requiring a higher level of NIH funding. The bill would affect taxpayers making qualifying donations, the research institutions that benefit from those donations, and the Oklahoma Tax Commission’s administration of the credit.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no direct floor or committee sentiment is available. Based on the bill text alone, the measure appears supportive of biomedical and cancer research by preserving the tax credit, while also imposing tighter caps and eligibility standards beginning in 2026. The absence of recorded opposition or amendments in the provided context suggests the bill had not yet generated documented public debate at the time of referral.
Contention
The main policy tension in HB2755 is between continuing tax incentives for research donations and limiting the fiscal cost to the state. Potential points of contention include the lower annual credit caps after 2025, the reduced cap for cancer research donations relative to biomedical research donations, and the higher NIH funding threshold for qualifying biomedical institutes, which could narrow eligibility. Business taxpayers may also focus on the new $25,000 limit for biomedical research donations, while research institutions may be concerned about whether the revised caps and formulas will reduce donor participation.